The CVT platform technology for TMVI is comprised of a bioprosthetic transcatheter mitral valve, a delivery catheter, and a loading system. The bioprosthesis design is based on a unique foreshortening frame designed to address the specific challenges of the mitral position, where elasticity and a lack of calcification preclude radial force, where there is minimal real estate for attachment in the left ventricle and where a risk of obstructing blood flow out of the left ventricle is present.
The CVT TMVI system for mitral heart valve replacement emphasizes anchoring, positioning, and control:
- ANCHORING – Secure annular attachment without radial force.
- POSITIONING – Self-positioning to native valve annulus.
- CONTROL – Multi-stage deployment and controlled release.
The CVT TMVI procedure is truly percutaneous and the access route is trans-venous, trans-septal and antegrade. Standard interventional cardiology techniques apply and the procedure is planned to take place in the cath lab or the hybrid OR.
TMVI offers the potential for a non-surgical definitive mitral valve therapy that may be as effective as surgical replacement and may be more effective than surgical or transcatheter repair while simultaneously lowering procedural risks and costs. It also represents a single technology/procedure that has the potential to address multiple types of mitral regurgitation and mitigate the challenges of the varying morphology of the disease.
|
|